Prestige Consumer Healthcare Inc. (PBH) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
As of 2026-11-03, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $49.73 (+1.37% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBH ranks #148 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable C (62/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and RCUS (Arcus Biosciences Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)
SEC XBRL FY 2025 (10-K): 22.6% FCF Margin ($246.4M FCF) & 54.7% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)
Even with a 62/100 (C) score, PBH faces multiple-compression risk if 12.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 52.2% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($48.42) or 200D SMA ($53.92) invalidates the momentum regime and cuts Target Base ($50.63) toward Bear Floor ($39.49).
Prestige Consumer Healthcare Inc. (PBH) advanced +1.37% to $49.73, trading at 25% of its 52-week range ($42.62 – $71.07). Solid 54.7% gross margin (14% return on capital), mixed timing at 12x P/E—hold if owned, no rush to chase.
Yahoo! Finance Canada report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Top contributors include AtriCure and Red Violet; top detractors include Kodiak Gas Services and PDF Solutions. Read more here.
GE HealthCare (GEHC) delivered earnings and revenue surprises of +10.74% and +2.87%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PBH today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PBH. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Prestige Consumer Healthcare Inc. (PBH) ranks #148 by composite RQD confidence (62/100, grade C) and #230 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PBH
ACTIVE
Prestige Consumer Healthcare Inc. | C | 62/100 | 12.1x | 54.7% | 13.8% | +1.37% | $2.32B | Benchmark Subject |
| BHVN Biohaven Ltd. | D | 44/100 | — | — | -35.0% | -1.69% | $2.33B | /bhvn-vs-pbh → |
| RCUS Arcus Biosciences Inc. | E | 19/100 | — | — | -35.0% | -1.87% | $2.32B | /rcus-vs-pbh → |
| PHVS Pharvaris N.V. | C- | 59/100 | — | — | — | 0.00% | $2.34B | /phvs-vs-pbh → |
| HCM HUTCHMED (China) Limited | E | 34/100 | 5.2x | — | -2.5% | +0.91% | $2.29B | /hcm-vs-pbh → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported GAAP revenue of $1.09B (-4.3% vs. FY2024 revenue of $1.14B , and -3.3% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $257.6M, and free cash flow of $246.4M (+1.3% YoY). On the balance sheet, PBH closed FY2025 with $3.49B in total assets against $0 in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $1.09B | $190.3M | $257.6M | $246.4M | $3.49B | — |
| FY2024 (FY) | 2025-03-31 | $1.14B | $214.6M | $251.5M | $243.3M | $3.33B | $1.00B |
| FY2023 (FY) | 2024-03-31 | $1.13B | $209.3M | $248.9M | $248.9M | — | — |
As of 2026-11-03, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $49.73 (+1.37% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 11/20, FRED Macro Regime Fit 11/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, PBH ranks #148 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable C (62/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and RCUS (Arcus Biosciences Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Institutional options positioning shows a 50% call / 50% put premium split.
PBH last traded at $49.73 (+1.37% on volume of 596,149 shares), positioning the stock +2.71% above its 50-day simple moving average ($48.42) and -7.77% below its 200-day simple moving average ($53.92). Across its 52-week range of $42.62 to $71.07, PBH sits at the 25.0% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($46.75 to $52.71).
Prestige Consumer Healthcare Inc. (PBH) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $49.73 (+1.37% 1D, market capitalization $2.32B).
Prestige Consumer Healthcare Inc. Is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies a market capitalization of $2.3B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported $1.09B in annual revenue (up from $1.14B in FY2024, -4.3% YoY) and $190.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.13B revenue, $209.3M net income) through FY2025, PBH scaled operating cash flow to $257.6M and free cash flow to $246.4M, backed by $3.49B in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PBH carries a macro regime beta of 1.00 and gross margin of 54.7%.
Real-time company headlines, analyst actions, and sector developments for Prestige Consumer Healthcare Inc. (PBH) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Prestige Consumer Healthcare Inc. (PBH) market action, institutional positioning, and fundamental catalysts.
The street is overcomplicating Prestige Consumer Healthcare Inc. (PBH). Insider conviction scores 17/20 and the FCF yield of 10.67% signals strong cash generation at a 12.1 trailing P/E.. With an RQD score of 62/100 (C) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $52.98.
@CreditSpread_Watch Shorting a 9/20 institutional whale-flow stock at $49.06 is dangerous when funds are rotating into Health Care.
I respect the product at Prestige Consumer Healthcare Inc., but the stock at $49.06 is a different story. Revenue and net income declined across FY 2024 to FY 2025 while institutional flow scores only 7/20.. FCF yield is 10.67% and RQD sits at 62/100 (C) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).